NBIX vs WELL · P/E 45, rev $1.77B vs P/E 100, rev $10.84B
Neurocrine Biosciences Inc (NBIX) versus Welltower Inc (WELL) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Welltower Inc (WELL) is a reit - healthcare facilities company listed on NYSE.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported WELL revenue for 2025-12-31 was $10.84B. Net income was $936.8M. Revenue was up 35.6% from 2024-12-31 to 2025-12-31. WELL currently screens at market cap $145.81B and trailing P/E 99.8.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. WELL currently screens at market cap $145.81B and trailing P/E 99.8.
Not investment advice. Open the NBIX and WELL stock pages for the full models.
Not investment advice.